Trial · NCT00045942
Results by group214
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 214
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Best Clinical Response (Core) | PKC412 in FLT3 Mutated Participants (Core) | 0 | Participants | ||
| Number of Participants With Overall Clinical Response (E1) | FLT3 Mutated PKC412 100 mg/Day (E1) | Complete response | 0 | Participants | |
| Number of Participants With Overall Clinical Response (E1) | FLT3 Mutated PKC412 200 mg/Day (E1) | Complete response | 0 | Participants | |
| Number of Participants With Overall Clinical Response (E1) | FLT3 Wild Type PKC412 100 mg/Day (E1) | Complete response | 0 | Participants | |
| Number of Participants With Overall Clinical Response (E1) | FLT3 Wild Type PKC412 200 mg/Day (E1) | Complete response | 0 | Participants | |
| Number of Participants With Overall Clinical Response (E1) | FLT3 Mutated PKC412 100 mg/Day (E1) | Partial response | 0 | Participants | |
| Number of Participants With Overall Clinical Response (E1) | FLT3 Mutated PKC412 200 mg/Day (E1) | Partial response | 1 | Participants | |
| Number of Participants With Overall Clinical Response (E1) | FLT3 Wild Type PKC412 100 mg/Day (E1) | Partial response | 0 | Participants | |
| Number of Participants With Overall Clinical Response (E1) | FLT3 Wild Type PKC412 200 mg/Day (E1) | Partial response | 0 | Participants | |
| Number of Participants With Overall Clinical Response (E1) | FLT3 Mutated PKC412 100 mg/Day (E1) | Minor response | 1 | Participants | |
| Number of Participants With Overall Clinical Response (E1) | FLT3 Mutated PKC412 200 mg/Day (E1) | Minor response | 0 | Participants | |
| Number of Participants With Overall Clinical Response (E1) | FLT3 Wild Type PKC412 100 mg/Day (E1) | Minor response | 6 | Participants | |
| Number of Participants With Overall Clinical Response (E1) | FLT3 Wild Type PKC412 200 mg/Day (E1) | Minor response | 3 | Participants | |
| Number of Participants With Overall Clinical Response (E1) | FLT3 Mutated PKC412 100 mg/Day (E1) | Blast response | 11 | Participants | |
| Number of Participants With Overall Clinical Response (E1) | FLT3 Mutated PKC412 200 mg/Day (E1) | Blast response | 12 | Participants | |
| Number of Participants With Overall Clinical Response (E1) | FLT3 Wild Type PKC412 100 mg/Day (E1) | Blast response | 15 | Participants | |
| Number of Participants With Overall Clinical Response (E1) | FLT3 Wild Type PKC412 200 mg/Day (E1) | Blast response | 8 | Participants | |
| Number of Participants With Overall Clinical Response (E1) | FLT3 Mutated PKC412 100 mg/Day (E1) | Overall response | 12 | Participants | |
| Number of Participants With Overall Clinical Response (E1) | FLT3 Mutated PKC412 200 mg/Day (E1) | Overall response | 13 | Participants | |
| Number of Participants With Overall Clinical Response (E1) | FLT3 Wild Type PKC412 100 mg/Day (E1) | Overall response | 21 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00045942/results